

Commissioning of Thoracic Oncology Services?

Mick Peake & Di Riley

NHS Commissioning Board

- Responsible for directly commissioning specialist health care services (those that can only be provided ‘efficiently and effectively’ at national level)
- Rare(r) cancers
- Specialist cancer services (e.g. Thoracic surgery, probably radiotherapy, etc.)
- Clinical Commissioning Advisory Groups:
 - Cancer (chair Sean Duffy)
 - Radiotherapy (chair Nick Slevin)
 - Radiosurgery - also National Stereotactic RT consortium group (chair Matthew Hatton)

Cancer Networks

- Ministerial support for cancer networks but recognition that they have been of variable quality and effectiveness
- McLean Review of Clinical Networks (wider than cancer – e.g. Cardiac) recently published
- Establishment of Specialist Clinical Networks (~15)
 - likely reduction of management support
 - greater emphasis on clinical leadership
- Likely to play a major role in commissioning at local level (link to specialist advice to Cancer Commissioning Boards – GPs)

Health & Well-being Boards

- Local authority chaired
- Bringing together primary & secondary care with public health and local authorities
- Heavy lay involvement
- May play an important role in public awareness campaigns in future

Quality drivers

- **National Guidance (NICE, etc.)**
- **NICE Quality Standards – Lung Cancer QS due out soon**
- **Commissioning Outcome Framework indicators (likely to be derived from NICE QS for cancer)**
- **CQUINs (at Trust level)**
- **National Cancer Action Team & NCIN Service Profiles and Service Specifications (mesothelioma under development, lung cancer during 2012)**
- **‘Third Sector’ (charities, etc) & public pressure**

Levels of Commissioning

- National level (<500 incidence)
- Specialized Commissioning Groups (~7.5m pop)
- Clinical Commissioning Groups (local)

Commissioning Support Packs

KEY
MESSAGES

www.cancertoolkit.co.uk

SERVICE
PROFILES

SERVICE
SPECIFICATION

Key messages on cancer (1)

- 1. The Incidence is rising:** - 250,000 new cases p.a. now; 300,000 by 2030
- 2. Cancer services and outcomes (survival and mortality) have improved** over the past 10–15 years. Much of the improvement has been in the hospital sector (MDTs etc)

Key messages on cancer (2)

3. Despite this, **survival for many cancers remains poor** in comparison with other developed countries
 - 5000 lives a year could be saved if we matched the European average (lung 750)
 - 10,000 lives a year could be saved if we achieved the level of the best (lung 1,300)
4. **Late diagnosis** is the major factor underlying the poor survival rates in this country

Key messages on cancer (3)

5. This is not simply a matter of patients living a few extra months.
 - Life to years, not years to life!
 - It can often be the difference between early death and long term survival/cure
6. Initiatives to promote early diagnosis are likely to be highly cost effective

Key messages on cancer (4)

7. Particular attention should be given to:
 - Reducing emergency presentations (23% of all cancers) as these have very poor survival
 - The elderly – who often present late
 - **Ensuring that providers record staging and report this to their cancer registry**

Service Specifications

- These may be by pathway or clinical speciality
- Services may be commissioned locally or by Specialist Commissioning groups
- Challenge – different commissioners?
 - Prevention & awareness - local
 - Diagnostics – local
 - Treatment - local, specialist, national
 - Rehabilitation - local
 - Supportive & palliative care - local

Key Service Outcomes

- Participation in National Audits
- Cancer waiting times
- Threshold for number of procedures, resection rates
- Length of stay/ readmission rates
- Recruitment into trials
- 30 day mortality, 1 & 5 year survival
- Registry data submissions – esp. staging
- National Cancer Patient Experience Survey

Service Profiles – what are they?

- One strand of commissioning support.
- Trust level information for commissioners
- A wide range of information from multiple sources to support the Service Specification
- Issue for Lung – local and specialist services

Service Profiles – supporting commissioning

- Collate a range of information in one place.
- Define indicators in a well-documented and clinically robust way.
- Provide site-specific information tied-in to relevant guidance.
- Allow easy comparison across the ‘providers’.
- Allow comparison to national benchmarks.

Cancer Service Profiles for Breast Cancer

Data displayed are for patients for which the trust of treatment can be identified. For a full description of the data and methods please refer to the 'Data Definitions' document. For advice on how to use the profiles and the consultation, please refer to 'Profiles guidance'. Please direct comments/feedback to service_profiles@ncin.org.uk

- Trust is significantly different from England mean
- Trust is not significantly different from England mean
- ◊ Statistical significance cannot be assessed
- ◆ England mean



National Cancer Action Team
Part of the National Cancer Programme



Section	#	Indicator	No. of patients/cases or value	Percentage or rate			Trust rate or percentage compared to England				Source	Period
				Trust	Lower 95% confidence limit	Upper 95% confidence limit	England	Lowest	Range	Highest		
Size	1	Number of new patients treated per year, 2010/11	169					63		759	CWT	2010/11
	2	Number of newly diagnosed patients treated per year, 2009	124					8		754	CWT/NCDR	2009
Demographics (based on newly diagnosed patients treated, 2009)	3	Patients aged 70+	46	37%	29%	46%	30%	13%		57%	CWT/NCDR	2009
	4	Patients with recorded ethnicity	115	93%	87%	96%	91%	73%		99%	CWT/NCDR	2009
	5	Patients with recorded ethnicity which is not White-British	2	2%	0%	6%	9%	0%		71%	CWT/NCDR	2009
	6	Patients who are Income Deprived (1)		25%		14%	6%			29%	CWT/NCDR	2009
	7	Male patients	3	2%	1%	7%	1%	0%		2%	CWT/NCDR	2009
	8	Patients with a nationally registered Nottingham Prognostic Index (NPI)	8	7%	3%	13%	50%	0%		88%	CWT/NCDR	2009
	9	Patients with a nationally registered NPI in excellent or good prognostic groups	n/a	n/a	n/a	n/a	62%	39%		73%	CWT/NCDR	2009
	10	Patients with Charlson co-morbidity index >0 (to be included in later profile release)									CWT/NCDR	2009
	Specialist Team	11	Does the specialist team have full membership? (2)	PR	Yes							NCPR
12		Proportion of peer review indicators met	PR	91%			76%				NCPR	2010/11
13		Peer review: are there immediate risks? (3)	PR	No							NCPR	2010/11
14		Peer review: are there serious concerns? (3)	PR	Yes							NCPR	2010/11
15		CPES (4): Patients surveyed and % reporting being given name of a CNS (5,6)	n/a	n/a			94%	73%		100%	CPES	2010
16		Surgeons not managing 30+ cases per year	1	25%	5%	70%	40%	0%		80%	HES	2009/10
Throughput	17	Number of urgent GP referrals for suspected cancer	1,299					307		4,126	CWT	2010/11
	18	Patients with invasive cancer and treated at this trust	168	99%	97%	100%	92%	52%		100%	CWT	2010/11
	19	Patients with non-invasive cancer and treated at this trust	1	1%	0%	3%	8%	0%		48%	CWT	2010/11
	20	Episodes following an emergency admission (new and existing cancers)	167	55%	49%	60%	37%	10%		71%	HES	2009/10
	21	Patients referred via the screening service	3	2%	1%	7%	33%	0%		64%	WMCIU	2009
Waiting times	22	Q2 2011/12: Urgent GP referral for suspected cancer seen within 2 weeks	306	99%	97%	100%	97%	68%		100%	CWT	2011/12 Q2
	23	Q2 2011/12: Treatment within 62 days of urgent GP referral for suspected cancer	27	100%	88%	100%	97%	86%		100%	CWT	2011/12 Q2
	24	Urgent GP referrals for suspected cancer diagnosed with cancer (to be included in later profile release)									CWT	2010/11
	25	Cases treated that are urgent GP referrals with suspected cancer									CWT	2010/11
	26	Q2 2011/12: First treatment began within 31 days of decision to treat	48	100%	93%	100%	99%	88%		100%	CWT	2011/12 Q2
Practice	27	Q2 2011/12: Urgent breast symptom referrals (cancer not suspected) seen in 2 wks	316	99%	98%	100%	96%	61%		100%	CWT	2011/12 Q2
	28	Surgical cases receiving sentinel lymph node biopsy	84	55%	47%	63%	43%	0%		76%	HES	2010/11
	29	Day case or one overnight stay surgery	134	74%	67%	79%	72%	28%		96%	HES	2010/11
	30	Mastectomy patients receiving immediate reconstruction	17	23%	15%	34%	19%	0%		73%	HES	2010/11
	31	Major surgeries in breast cancer patients (including in-situ cases)	98	79%	71%	85%	74%	50%		87%	HES/NCDR	2009
	32	Surgical patients receiving mastectomies	72	52%	44%	60%	39%	22%		69%	HES	2009/10
	33	Mean length of episode for elective admissions	2.4				2.8	0.7		6.3	HES	2009/10
	34	Mean length of episode for emergency admissions	4.7				4.9	2.4		11.3	HES	2009/10
Outcomes and Recovery	35	Surgical patients readmitted as an emergency within 28 days	7	4%	2%	8%	4%	1%		15%	HES	2010/11
	36	Q2-Q4 2010/11: First outpatient appointments of all outpatient appointments	3,654	41%	40%	42%	43%	23%		71%	PBR SUS	2010/11 Q2-Q4
	37	Patients treated surviving at one year (to be included in later profile release)										
Patient Experience - CPES (4)	38	Patients surveyed & % reporting always being treated with respect & dignity (6)	n/a	n/a			82%	65%		95%	CPES	2010
	39	Number of survey questions and % of those questions scoring red						0%		70%	CPES	2010
	40	and green (7)						0%		72%	CPES	2010

Definitions: (1) Based on patient postcode and uses the Index of Multiple Deprivation (IMD) 2010; (2) Peer Review (NCPR) source - IV=Internal Verification, PR= Peer Review, EA= Earned Autonomy; (3) The immediate risks or serious concerns may now have been resolved or have an action plan in place for resolution; (4) CPES = Cancer Patient Experience Survey; (5) CNS = Clinical Nurse Specialist; (6) Italic value = total number of survey respondents for tumour group. (7) Based on scoring method used by the Department of Health - red/green scores given for survey questions where the trust was in the lowest or highest 20% of all trusts. Questions with lower than 20 respondents were not given a score. Italic value displayed = the total number of viable survey questions, used as the denominator to calculate the % of red/greens for the trust.
n/a = not applicable or not available

Clinical Aspects - Breast

Practice	28	Surgical cases receiving sentinel lymph node biopsy
	29	Day case or one overnight stay surgery
	30	Mastectomy patients receiving immediate reconstruction
	31	Major surgeries in breast cancer patients (including in-situ cases)
	32	Surgical patients receiving mastectomies
	33	Mean length of episode for elective admissions
	34	Mean length of episode for emergency admissions
Outcomes and Recovery	35	Surgical patients readmitted as an emergency within 28 days
	36	Q2-Q4 2010/11: First outpatient appointments of all outpatient appointments
	37	Patients treated surviving at one year (to be included in later profile release)

What do we need for lung?

What is local & what nationally commissioned?

Summary

- There is a new commissioning landscape in development
- Services will be commissioned at different levels some still to be determined
- Cancer networks and their clinical tumour groups will have a role to play
- The service profiles will be an important element within commissioning support – but need clinical input to fulfil their potential.